Who actually signs
At a biotech between twenty and five hundred people, the signer is the VP of clinical operations or the chief medical officer, and the champion is the clinical trial manager who has been handed a site activation timeline that the funding runway does not support. At a company running its first phase two trial, there may be one clinical operations person, recently hired, and a contract research organization that was selected before that person arrived.
The buying reason is time. Every month a trial runs past plan is a month of runway, and site activation is the phase where the months are lost, in contracts, budgets, ethics approvals and regulatory documents that move at the pace of the slowest site.
The one sentence version
Your buyer is a clinical operations leader with a trial registered as not yet recruiting, a site activation plan measured in months, a contract research organization whose startup team is stretched across twelve sponsors, and a board that funded a first patient date.
The triggers, and where each one is visible
- Trial registrations. The public registry lists every trial with sponsor, phase, therapeutic area, planned enrollment, site count and status. A phase two or three trial at a small sponsor with status not yet recruiting is a site startup engagement that has not been staffed, and the registration date tells you how recently.
- Investigational application clearances. Sponsors announce when the regulator has cleared the application to begin a trial, because it is a milestone investors care about. The announcement is public and the trial registration follows within weeks.
- Pushed completion dates. The registry keeps history. A trial whose estimated completion date has moved once is slow. One that has moved twice is an enrollment problem with a public record, and the sponsor knows which sites are enrolling zero.
- Funding at clinical stage. A round announced as funding a phase two or three program is a round funding site activation, and the press release names the program.
- Clinical operations job posts. A sponsor advertising for its first clinical trial manager or a site startup lead has a trial coming and no one to activate the sites. The posting is usually up for months.
- Expedited designations. A breakthrough or fast track designation for a drug is a public announcement that the sponsor's timeline just got shorter and its site activation just got more urgent.
- Contract research organization selections. Sponsors announce them, and a sponsor that just selected one is about to discover how long the organization's site startup queue is.
The registrations with status not yet recruiting and the pushed completion dates are the two to build on. One tells you who is about to activate sites. The other tells you whose sites did not work.
Qualify in sixty seconds
- Is it phase two or three with multiple sites? A single site phase one trial does not need you. A forty site phase three does, badly.
- Is the sponsor small enough to outsource and large enough to fund it? Fifty to five hundred employees is the range where a sponsor has a trial, a runway and no site startup function.
- Is the therapeutic area one you know? Site relationships and feasibility data are therapeutic area specific, and a sponsor can tell in one call whether you have activated sites in theirs.
- Is there a contract research organization engaged, and is site startup in its scope? Often the organization's scope covers monitoring and data and leaves activation to the sponsor, which is the opening. Sometimes activation is in scope and slow, which is a different opening.
The angle that gets replies
Lead with the activation timeline and the first patient date. The clinical operations leader has a board slide with a first patient date on it and a private estimate of how late it will be. Name the gap and offer to close part of it.
Three openers you can adapt
- On a registration with status not yet recruiting"Saw the phase two registration with twenty planned sites and a not yet recruiting status. At that site count, activation typically runs five to seven months from the first regulatory package to the last site initiated, and the spread between the fastest and slowest site is where the first patient date is lost. We run activation in parallel across sites rather than in sequence, and the difference is usually two to three months. One page on how, attached to nothing."
- On a trial whose completion date has moved twice"The registry shows the estimated completion date on your phase three moving twice this year. In our experience that pattern means a third of the sites are enrolling nothing while the others carry the trial. A site performance review and a targeted rescue plan, adding sites in the geographies that are enrolling and closing the ones that are not, is about three weeks to plan and starts moving enrollment in the second month. Happy to scope it."
- On a first clinical trial manager posting"Saw the clinical trial manager posting. The hire will arrive to a site activation plan that is already running, and the two things most first trial managers inherit are a feasibility questionnaire that did not predict which sites would enroll and a contract queue at the organization that nobody owns. Both can be fixed before the start date. Two paragraphs on the feasibility approach that actually predicts enrollment, attached."
Each one names the trial, the number and the timeline, in the clinical operations vocabulary, and offers a small piece of the plan. That is a peer writing to a peer.
What not to send
- "Full service clinical research organization" if you are not one. The reader has one, is frustrated with it, and does not want a second.
- "Global site network" as the pitch. Site networks are sold by everyone and the reader's problem is specific sites in specific geographies enrolling specific patients.
- "We accelerate enrollment" with no number. Every vendor in the space claims it. The activation timeline in months and the enrollment rate per site per month are the numbers, and the note should have them.
- Ignoring the contract research organization already engaged. The sponsor chose it, is paying it, and will not replace it mid trial. Position alongside it or the note dies.
The objection you will hit
Our contract research organization handles site startup. Ask what the activation timeline in the contract says and how many sponsors the organization's startup team is supporting this quarter. The organization's queue is the bottleneck in most delayed trials, and the sponsor has usually not been told where in the queue their trial sits. Specialist startup alongside the organization is common, and the organization often prefers it because it takes the slowest phase off their plate.
The second is we have sites from the last trial. Some of which enrolled and some of which did not, and the ones that did not will be on the list again unless someone looks at the performance data. A third of sites in a typical trial enroll nothing. Feasibility that uses the last trial's actual enrollment by site, rather than a questionnaire, is the answer.
The third is we will manage it in house. With the one clinical trial manager who has not started yet. The activation runs on the calendar regardless, and the engagement is the bridge until the hire lands and the method the hire inherits.
Deal shape
- Feasibility study using site level historical performance rather than questionnaires: commonly $15K to $60K depending on site count and geography.
- Site identification and startup, per site: $5K to $15K, covering regulatory package, contracts, budgets and ethics submissions through initiation.
- Enrollment rescue, including site performance review, site additions and closures: $50K to $300K depending on the trial.
- Startup retainer for a sponsor with several trials: $10K to $30K a month.
- Signer: VP Clinical Operations or Chief Medical Officer. Champion: the clinical trial manager. Cycle: two to eight weeks, and days when a completion date has just moved.
The feasibility study is the funnel. It is small, it is about a trial that is already registered, and it produces the site list with predicted enrollment, which is the startup engagement.
A cadence you can actually run
- Weekly, pull new phase two and three registrations with status not yet recruiting at sponsors under five hundred employees in your therapeutic areas.
- Weekly, pull registry history for trials whose estimated completion date has moved, and flag those that have moved twice.
- Weekly, pull investigational application clearances, expedited designations and clinical stage funding announcements.
- Monthly, pull clinical operations and site startup job posts and note their age.
- Qualify against the four checks, with the phase and site count first. One message per account, naming the trial and the timeline. Fifteen to twenty accounts a week is a full program.
- Three touches over two weeks, then stop. The next status change on the registry is a fresh reason to write, and the registry changes every week.
The sponsor registers the trial before it recruits and the registry records when it stalls. The firms that grow are the ones writing to the not yet recruiting list every Monday.
The sending mechanics most people get wrong
Everything above is about who and what. This is about how, and it is where most outbound in this niche quietly dies. Seven rules. None of them are optional.
1.Three to five sentences. That is the whole email.
Your reader is on a phone between meetings. One observable fact about their company, one consequence they have not thought about, one specific thing you would do. Anything past five sentences is a memo, and memos get archived unread.
2.Lead with a technical differentiator that turns into a number.
The messages that work best name something concrete you do differently and translate it into time or money saved. In this niche the differentiator is activation time and enrollment prediction. A firm that can say its median days from regulatory package to site initiation across its last dozen trials, and what fraction of the sites its feasibility predicted would enroll actually did, has the two numbers a clinical operations leader will check against their own experience. State both, with the trial count behind them.
Most services firms do not have a technical differentiator, and pretending to have one reads as exactly that. The substitute is a verticalized case study: a company like theirs, what you did, what happened, in one sentence. For this niche the line is: a 90 person oncology biotech, phase two registered as not yet recruiting in February, feasibility from site level historical data in three weeks, eighteen sites activated in parallel with the last initiated four months after the first package, first patient enrolled a stated number of weeks ahead of the board date, no sites enrolling zero at month six. The four months and the zero idle sites are what the reader will check.
3.Ten to twenty emails a day per mailbox. Not a hundred.
Sender reputation is scored per mailbox and per sending domain. One inbox pushing a hundred cold emails a day looks like exactly what it is, and the penalty lands on the domain, which means it lands on your client correspondence too.
If the math says you need more volume, the answer is more mailboxes on more warmed sending domains, separate from the domain you invoice from. It is never more volume per mailbox. Fifteen to twenty accounts a week at three touches is nine to twelve emails a day, one warmed mailbox. The registry produces a steady weekly list rather than spikes, so a second mailbox is only needed if you add therapeutic areas.
4.Write ten versions of every step and test them.
Versions A through J, not A and B. Rotate subject lines and bodies. You learn which angle is actually working instead of guessing, and there is a second reason that matters more: identical bodies going out over and over is one of the patterns postmaster tools flag. Variation is a deliverability tool as much as a testing one.
Subject line seeds for this niche, each of which should become several variants: "twenty sites and not yet recruiting", "the completion date that moved twice", "before your trial manager starts". Lower case, no punctuation tricks, and nothing that would look odd in a reply from a colleague.
5.Stop at three.
Most replies arrive on the first and second email. The third is already thin. Every touch past that raises the odds the whole thread gets classified as spam, and that classification follows the mailbox to the next person you write to. The long cadence is over. Three touches, each with something new in it, then leave them alone for ninety days.
6.Know what good looks like.
A one percent reply rate with a quarter of those replies positive is a healthy trigger based program. Anyone quoting you double digit reply rates is counting out of office messages or selling a course.
7.LinkedIn Sales Navigator is not optional.
Every other data source tells you who held a title at some point. Sales Navigator tells you who holds it today, because the person maintains it themselves. That is the difference between a three percent bounce rate and a fifteen percent one, and bounces are scored against the mailbox the same way spam complaints are. Verify the name there before anything goes out.
It is also the cheapest trigger detector you will own. The job change filter surfaces people who arrived in a role in the last ninety days, which is the moment they have budget and no incumbent. The posted recently filter surfaces companies talking about the exact problem you solve. Account lists with headcount growth alerts tell you who is scaling before the press release does. For this niche the saved search is headcount 20 to 500 in biotechnology and pharmaceuticals, titles VP Clinical Operations, Chief Medical Officer, Clinical Trial Manager and Director of Clinical Operations, with the job change alert on for clinical operations leadership and a keyword alert on clinical trial manager and site startup across job listings. Navigator confirms the person. The trial registry is the source, and it is the best public prospecting database in any niche on this site.
Use it for the research and the verification, not for the message. InMail reply rates are a fraction of email, and the person who replies to a thoughtful email is the same person who ignores a connection request with a pitch attached. Pull the work email from a data provider once Navigator has confirmed the person is real and current.
None of this is specific to your niche. All of it is specific to whether anyone ever reads the angle you spent an hour getting right.
If you would rather not run it yourself
That is what we do. ExpertLayer runs this exact loop for expert led firms: the weekly registry pull with the filters above, the completion date history check, the qualification with the phase and site count first, the angle per account naming the trial, the sending across warmed mailboxes, and the reply reading. You take the conversations and run the feasibility.
The first step is free and it is the same research described above. Send us your website and we will come back with 10 companies that hit these triggers right now, with the registration or date change, the contact, and the opening line for each.
Questions from people running this
Sponsors or contract research organizations?+
Small and mid sized sponsors for a boutique, because the buyer is a VP of clinical operations who can sign and the trigger is a trial registration they filed themselves. Large contract research organizations are both a channel and a competitor, and selling to them means becoming a subcontractor on their terms. Sponsors first, and the organizations follow when a sponsor asks them to use you.
The trial registry shows every trial. How do I not drown in it?+
Filter hard. Phase two and three, status not yet recruiting, sponsor with fewer than five hundred employees, therapeutic areas you know. That cut takes a registry of tens of thousands to a weekly list of a few dozen sponsors who are about to activate sites and have nobody to do it.
Is a trial with a pushed completion date really a good prospect, or a lost cause?+
The best prospect in the niche, because the sponsor has a public problem with a date on it. A completion date that has moved twice on the registry is an enrollment problem, and enrollment rescue is a well defined engagement with an urgent buyer. Write to them about the sites that are enrolling zero, which the sponsor knows and has not acted on.
The updated clinical practice guideline, worth mentioning?+
Yes, to sponsors running their first trial under it. The revised guideline emphasizes risk based approaches and proportionate oversight, sponsors are expected to work to it now, and a small sponsor that wrote its site startup procedures under the old version has a gap. It is a credential in a sentence, not a lead, so keep it to one line.